Biomea Fusion (BMEA) Stock: Buy, Sell, or Hold?
BMEA - Biomea Fusion, Inc. Common Stock
$0.87
0.03 (3.89%)
▲
5d:
-38.81%
30d:
-51.46%
90d:
-33.67%
WAIT
LOW Confidence
Analysis Updated: Oct 16, 2026 12:00 AM ET
Earnings: Nov 03, 2026
16d
Get Alerted When BMEA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: BMEA is down 38.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: BMEA is down 38.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: BMEA is currently trading at $0.87, which is considered oversold relative to its 30-day fair value range of $1.15 to $1.75.
Technical Outlook: Technically, BMEA is in a downtrend. Immediate support is located at $0.80, while resistance sits at $1.46. The stock is showing strong short-term momentum, up 3.9% recently.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.57 (+656.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BMEA is in a downtrend. Immediate support is located at $0.80, while resistance sits at $1.46. The stock is showing strong short-term momentum, up 3.9% recently.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.57 (+656.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.15 -
$1.75
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
87.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (43/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.9%)
- BULLISH: Trading 656.3% below Wall St target ($6.57)
- WARNING: Composite score 48/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.15 -
$1.75
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.80
Resistance Level
$1.46
Current Trend
Downtrend
Technical data as of
Oct 16, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.92
Wall Street Target
$6.57
(+656.3%)
Share & Embed Analysis
Last updated: October 17, 2026 4:21 AM ET
Data refreshes hourly during market hours. Next update: 5:21 AM
Data refreshes hourly during market hours. Next update: 5:21 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BMEA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1180 | 64 BUY |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 63 BUY |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 46 HOLD |
|
SYRE
Spyre Therapeutics Inc. |
STRONG BUY
17 analysts |
$120 | 55 HOLD |
|
ROIV
Roivant Sciences Ltd |
STRONG BUY
13 analysts |
$48 | 73 BUY |
